U.S. markets closed

Zymeworks Inc. (ZYME)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.86+1.31 (+2.70%)
At close: 1:00PM EST

49.86 0.00 (0.00%)
After hours: 1:15PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close48.55
Open48.55
Bid40.38 x 800
Ask52.60 x 900
Day's Range48.21 - 52.60
52 Week Range20.33 - 52.75
Volume306,994
Avg. Volume441,146
Market Cap2.285B
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-4.43
Earnings DateNov 03, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer
    Business Wire

    Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

    Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.

  • The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
    Benzinga

    The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) * Aligos Therapeutics Inc (NASDAQ: ALGS) (announced multiple presentations at the Liver Meeting) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Champions Oncology Inc (NASDAQ: CSBR) * CureVac BV (NASDAQ: CVAC)(announced a vaccine supply deal with the European Commission) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Generation Bio Co (NASDAQ: GBIO) * Immunovant Inc (NASDAQ: IMVT) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kazia Therapeutics Ltd (NASDAQ: KZIA) * Keros Therapeutics Inc (NASDAQ: KROS) * Moderna Inc (NASDAQ: MRNA) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) * Myokardia Inc (NASDAQ: MYOK) * Neuronetics Inc (NASDAQ: STIM) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Oncorus Inc (NASDAQ: ONCR) * Pacira Biosciences Inc (NASDAQ: PCRX) * Shockwave Medical Inc (NASDAQ: SWAV) * Spruce Biosciences Inc (NASDAQ: SPRB) * Summit Therapeutics Inc (NASDAQ: SMMT) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) * Trinity Biotech plc (NASDAQ: TRIB) * United Therapeutics Corporation (NASDAQ: UTHR) * Veracyte Inc (NASDAQ: VCYT) * Vericel Corp (NASDAQ: VCEL) * Zai Lab Ltd - ADR (NASDAQ: ZLAB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 16) * 180 Life Sciences Corp (NASDAQ: ATNF) * Jaguar Health Inc (NASDAQ: JAGX) * Kiromic Biopharma Inc (NASDAQ: KRBP) * PMV Pharmaceuticals Inc (NASDAQ: PMVP)Stocks In Focus Bristol-Myers Squibb Announces Delay In Regulatory Review Period For Lymphoma Treatment Candidate Bristol-Myers Squibb Co (NYSE: BMY) said the FDA has informed it that its review of the BLA for lisocabtagene maraleucel (liso-cel) for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least two prior therapies will not be completed by the PDUFA action date of Nov. 16. This is due to the agency's inability to inspect a third-party manufacturing facility in Texas during the current review cycle due to travel restrictions related to the COVID-19 pandemic.The FDA did not provide a new anticipated action date.Alkermes Schizophrenia Drug Fails to Win FDA Nod Alkermes Plc (NASDAQ: ALKS) said the FDA has issued a complete response letter regarding its new drug application for ALKS 3831 for the treatment of adults with schizophrenia and adults with bipolar I disorder."Following a remote review of manufacturing records, FDA stated that resolution of certain conditions related to the tablet coating process at the company's Wilmington, OH facility is required before ALKS 3831 may be approved," the company said.The CRL did not identify or raise any concerns about the clinical or non-clinical data in the NDA and the FDA has not asked Alkermes to complete any new clinical trials to support approval of the application.ALX, Zymeworks Announce Collaboration to Study Oncology Drug Combination In Breast Cancer, Solid Tumors ALX Oncology Holdings Inc (NASDAQ: ALXO) and Zymeworks Inc (NYSE: ZYME) said they have entered into a clinical collaboration to evaluate the combination of Zymeworks' zanidatamab, a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors.The agreement provides for Zymeworks conducting a Phase 1b study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study. The first part of the trial will evaluate the safety of the combination treatment. The second part of the trial will evaluate the safety, tolerability and anti-tumor activity of the combination in separate cohorts of subjects with HER2-positive breast cancer, HER2-low breast cancer, and non-breast HER2-expressing solid tumors.RA Medical to Being Trading On Reverse Split-adjusted Basis RA Medical Systems Inc (NYSE: RMED) said its 1-for-25 reverse stock split will become effective at 5:00 pm, Nov. 16. The shares will begin trading on a split-adjusted basis on the NYSE, beginning Nov. 17The stock plunged 14.23% to 18 cents in after-hours trading.Boston Scientific Voluntarily Recalls Aortic Valve System, to Discontinue The Product Boston Scientific Corporation (NYSE: BSX) said it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge Aortic Valve System due to complexities associated with the product delivery system. The voluntary recall is related solely to the delivery system, as the valve continues to achieve positive and clinically effective performance post-implant. There is no safety issue for patients who currently have an implanted LOTUS Edge valve, the company said.Given the additional time and investment required to develop and reintroduce an enhanced delivery system, the company said it has chosen to retire the entire LOTUS product platform immediately.View more earnings on IBBThe company expects to incur total pre-tax GAAP charges of approximately $225 million to $300 million related to the decision, with $100 million to $150 million likely to affect adjusted results.Earnings Summit Therapeutics Inc (NASDAQ: SMMT) reported third-quarter revenues of $181,000 in 2020 compared to 148,000 in 2019. The net loss per share widened from 20 cents to 26 cents, while analysts estimated a loss of 1 cent per share. The company also said it is withdrawing the timeline it had earlier publicly declared for the completion of the Phase 3 Ri-CoDIFy trials of ridinilazole in C. difficile infection.The stock slipped 14.46% to $4.20 in after-hours trading.PLx Pharma Inc (NASDAQ: PLXP) reported no revenues for the third quarter of 2020 compared to $41,106 million in the year-ago period. The company reversed to a loss of 40 cents from a profit of 9 cents. Analysts had estimated a wider loss of 42 cents per share,The company also said it has submitted two chemistry and manufacturing control supplemental new drug applications one for VAZALORE 325 mg and one for VAZALORE 81 mg dose to the FDA in October for regulatory approval.The stock moved down 8.03% to $4.01 in after-hours trading.Co-Diagnostics Inc's (NASDAQ: CODX) reported below-consensus third-quarter EPS despite a strong increase in revenues.Separately, the company announced CE mark approval for Logix Smart ABC (Influenza A/B, SARS-CoV-2) and its Logix Smart SARS-CoV-2 (genes RdRp/E) multiplex test for multiple targets of the SARS-CoV-2 genome.In premarket trading, the stock was down 16.11% to $11.40.On The Radar Clinical Readouts/Presentations Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.Earnings Trinity Biotech plc (NASDAQ: TRIB) (before the market open) PAVmed Inc (NASDAQ: PAVM)See more from Benzinga * Click here for options trades from Benzinga * The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets * The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
    Business Wire

    Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

    Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced they have entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab (formerly ZW25), a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors.